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Abstract 
We have previously demonstrated that the thiazolidinedione ciglitazone inhibited, 
independently of PPARγ activation, melanoma cell growth. Further investigations now 
show that ciglitazone effects are mediated through the regulation of secreted factors. Q-
PCR screening of several genes involved in melanoma biology reveals that ciglitazone 
inhibits expression of the CXCL1 chemokine gene. CXCL1 is overexpressed in 
melanoma and contributes to tumorigenicity. We show that ciglitazone induces a 
diminution of CXCL1 level in different human melanoma cell lines. This effect is 
mediated by the down regulation of microphthalmia-associated transcription factor, 
MITF, the master gene in melanocyte differentiation and involved in melanoma 
development. Further, recombinant CXCL1 protein is sufficient to abrogate 
thiazolidinedione effects such as apoptosis induction, while extinction of the CXCL1 
pathway mimics phenotypic changes observed in response to ciglitazone. Finally, 
inhibition of human melanoma tumor development in nude mice treated with ciglitazone 
is associated with a strong decrease in MITF and CXCL1 levels.  
Our results demonstrate that anti-melanoma effects of thiazolidinediones involve an 
inhibition of the MITF/CXCL1 axis and highlight the key role of this specific pathway in 
melanoma malignancy. (178 words) 
 
 
Keywords: melanoma, thiazolidinedione, chemokine, MITF, apoptosis. 
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Introduction  
 
Cutaneous melanoma is an aggressive skin cancer that originates from epidermal 
melanocytes. Typically, primary lesions progress to malignant tumors through a multistep 
process including dysplasia, radial growth phase (RGP), invasive vertical growth phase 
(VGP), and metastasis. This transition is accomplished through the accumulation of genetic 
alterations in growth control pathways including oncogenic mutations or gene amplification. 
For example, constitutive activation of the Ras/MAPkinase-signaling pathway is frequently 
observed in melanomas, as a consequence of activating mutations of the B-Raf and N-Ras 
genes 1-3. Melanoma progression is also accompanied by generation of autocrine and 
paracrine loops associated with the aberrant production and secretion of growth factors and 
chemokines that sustain growth, survival and invasion 4. 
In human, melanoma is one of the most lethal cancers among young adults. Melanoma has a 
high capability of invasion and rapid metastasis to other organs. The prognosis of metastatic 
melanoma is extremely dismal, as the various treatments have not shown survival benefit 5. It 
appears thus necessary to develop approaches enabling the discovery of new molecular 
targets, candidates for specific biotherapy treatment of this disease.  
Thiazolidinediones (TZD) regulate transcriptional activity of the nuclear receptor 
Peroxysome Proliferator Activated Receptor gamma (PPARγ) and are currently used in type 
II diabetes treatment. More recently, TZD have been reported to inhibit proliferation and 
survival of numerous cancer cells 6-11. Furthermore, we have previously demonstrated that 
ciglitazone, that belongs to TZD family, inhibits growth and viability of melanoma cells 
without affecting normal melanocyte growth 12.  
To further investigate the molecular events elicited by ciglitazone and to better understand the 
implication of TZD signaling in melanoma biology, we examined whether ciglitazone affects 
the production of autocrine and paracrine factors known to be implicated in melanoma 
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malignancy. In the present report, we demonstrate that ciglitazone inhibits the expression of 
(C-X-C motif) ligand 1 (CXCL1), a chemokine involved in melanoma growth, survival, 
angiogenesis and metastasis 13-16. Interestingly, ciglitazone treatment decreases CXCL1 level 
in various human melanoma cell lines but not in normal human melanocytes. We also show 
that treatment of melanoma cells with recombinant CXCL1 compensates for the loss of 
endogenous CXCL1 secretion induced by ciglitazone and abolishes the loss of viability of 
melanoma cells. Further, CXCL1 inhibition by ciglitazone is mediated by the decrease in 
MITF expression. CXCL1 appears to be a new target gene of microphthalmia-associated 
transcription factor (MITF), the master gene of melanocyte differentiation that was also 
involved in melanoma development 17-21. Finally, we demonstrate that a dramatic inhibition of 
melanoma xenograft development in mice in response to ciglitazone is associated with a 
decrease in MITF gene expression and in circulating CXCL1 level. 
Our results demonstrate for the first time that ciglitazone-induced apoptosis of melanoma 
involves an inhibition of a MITF/CXCL1 signaling cascade. 
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Results 
Effect of ciglitazone on CXCL1 expression and secretion 
We first determined whether the biological effects of ciglitazone in melanoma cells were 
mediated by secreted factors. We confirmed that ciglitazone did not affect normal human 
melanocytes (NHM) viability (Fig. 1A). 
In contrast, the number of melanocytes was significantly reduced when incubated in presence 
of conditioned medium from A375 melanoma cells exposed to ciglitazone compared to 
conditioned medium from DMSO-treated A375 cells (Fig. 1B). These results suggest that the 
inhibition of melanoma cells growth or survival elicited by ciglitazone was at least in part 
mediated by secreted factors. 
To substantiate this observation, we analyzed by quantitative-PCR, the expression of 19 
transcripts encoding for proteins known to be secreted by melanoma (Table 1). Among them 
ciglitazone clearly repressed the expression of CXCL1. Due to the important role of the 
CXCL1 chemokine in melanoma progression, we decided to investigate thoroughly the 
involvement of this cytokine in the effect of ciglitazone on melanoma cells.  
RT-QPCR analysis confirmed a dose-dependent downregulation of CXCL1 expression in 
ciglitazone-treated A375 melanoma cells (Fig. 2A). Then, we demonstrated a decrease in 
CXCL1 cytoplasmic protein by immunofluorescence (Fig. 2B). TNFα, an activator of NF-κB 
pathway, significantly increased CXCL1 level. To confirm the presence of CXCL1 receptor, 
CXCR2 labeling was carried out (Fig. 2B, lower part). A375 cells expressed CXCR2 receptor 
and ciglitazone did not change its expression.  
CXCL1 amount in medium was evaluated by ELISA. TNFα increased CXCL1 level while 
ciglitazone induced a dose-dependent reduction of CXCL1 in both basal and TNFα conditions 
(Fig. 2C). Western blot of the secreted matricellular SPARC protein was used as loading 
control. 
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Relationship between CXCL1 downregulation and cell viability inhibition induced by 
ciglitazone 
One could think that the inhibition of CXCL1 is the consequence of the decrease in cell 
viability induced by ciglitazone. However, reduction of CXCL1 was detectable after 2h and 
therefore could not result from the decrease in viability of cells that was observed after 12h 
(Fig. 3A). In contrast, the slight decrease in CXCL1 level observed after 12h to 48h of 
staurosporine treatment appeared to be the consequence of cell death induced by this agent. 
Next, other TZD, pioglitazone and rosiglitazone had no significant effect on CXCL1 secretion 
(Fig. 3B). In contrast, troglitazone showed a dose-dependent decrease in CXCL1 level 
comparable to that observed with ciglitazone. Moreover, the decrease in CXCL1 level in 
response to ciglitazone treatment was still observable when PPARγ expression was abrogated 
by siRNA silencing, indicating that ciglitazone acts independently of PPARγ to repress 
CXCL1 expression (Fig. S1) 
Interestingly, no CXCL1 was detectable in NHM (Fig. 3C). However, treatment of 
melanocytes by TNFα induced an increase in the level of CXCL1 that was not modulated by 
ciglitazone. Ciglitazone was unable to control CXCL1 expression in melanocytes.  
Finally, we tested ciglitazone on different tumor cell lines. SK-Mel-28, WM793 and 1205 Lu 
melanoma cells had basal CXCL1 levels comparable to that found in A375 while MeWo had 
very low CXCL1 level. In all melanoma cells, TNFα induced a significant increase in CXCL1 
level and ciglitazone decreased strongly the chemokine level. In contrast to neuroblastoma 
cells SH-SY5Y, prostate tumor cells PC-3 presented a high CXCL1 basal level. As in 
melanoma cells, TNFα significantly increased the cytokine level in both cell lines while 
ciglitazone strongly reduced CXCL1 level (Fig. 3D). The effects of ciglitazone on growth and 
survival in these cell lines were tested (Fig. 3E and S2). Ciglitazone treatment decreased cell 
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number in all tumor cell lines tested so far. However, the most striking effect was observed in 
melanoma cell lines with a high basal CXCL1 level. 
 
Effect of recombinant CXCL1 on the decrease in cell viability induced by ciglitazone  
To determine whether CXCL1 inhibition played an important role in ciglitazone-induced loss 
of melanoma cell viability, we compensated the loss of endogenous CXCL1 by adding human 
recombinant CXCL1 (rCXCL1). As expected, ciglitazone (10µM) induced a loss of 65% of 
cell viability (Fig. 4A). Addition of rCXCL1 prevented in a dose-dependent manner the loss 
of cell viability. Similarly, the reduction of cell viability induced by ciglitazone was reversed 
by TNFα (Fig. 4B). Consequently, rCXCL1 as well as the TNFα-induced CXCL1 increase 
induced by TNFα had a protective effect against ciglitazone action.  
Interestingly, rCXCL1 did not prevent cell viability reduction mediated by two apoptosis 
inductors, TRAIL and staurosporine (Fig. 4C). The protective effect of rCXCL1 thus seems 
specific of the ciglitazone action.  
We have previously established that low concentrations of ciglitazone induced a G0/G1 cell 
cycle arrest of A375 melanoma cells. Our results demonstrated that rCXCL1 was able to 
reverse ciglitazone-induced cell cycle arrest (Fig. S3). 
We have also shown that high concentrations of ciglitazone induced melanoma cells 
apoptosis. We observed that 10µM ciglitazone induced the disappearance of the zymogenic 
form of caspases 3, 8 and 9 as well as a cleavage of poly(ADP-ribose) polymerase (PARP). 
Consistently with the protective effect of rCXCL1, cleavage of caspases and  PARP evoked 
by 10μM ciglitazone were not detected in presence of rCXCL1 (Fig. 5A). These results were 
confirmed by caspase 3, 8 and 9 activation assays (Fig. 5B). Interestingly, rCXCL1 was not 
able to prevent the activation of these three caspases induced by staurosporine. Further, flow 
cytometry analysis showed that rCXCL1 blocked the accumulation of cell in sub-G1 (Fig. S3) 
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and prevented the increase in annexin-V labeling (Fig. 5C), both induced by ciglitazone. In 
conclusion, CXCL1 protects melanoma cells from apoptosis induced by ciglitazone.  
Our observations prompted us to check whether CXCL1 inhibition was sufficient to reduce 
melanoma cell viability. Transfection of A375 cells with increasing concentrations of si-
CXCL1 induced a strong and dose dependent reduction of the CXCL1 protein level (Fig. 6A). 
Using XTT assay, we observed that A375 cells transfected with si-CXCL1 showed a dose-
dependent reduction of cell viability reaching 50% decrease at 50 nM of si-CXCL1 (Fig. 6B). 
Addition of rCXCL1 completely restored the cell viability. Then, we observed a dose-
dependent reduction of A375 cell viability in the presence of anti-CXCL1 neutralizing 
antibodies (Fig. 6C). No significant reduction in the viability of these cells was detected in 
presence of control antibodies.  
We next showed that CXCL1 silencing induced the activation of caspases 9, 8 and 3 (Fig. 6D) 
as well as an increase in annexin-V labeling (Fig. 6E). Taken together, these results indicate 
that the inhibition of CXCL1 production is sufficient to induce apoptosis in melanoma cells. 
In the same way, inhibition of CXCR2 signaling by neutralizing antibody or pharmacological 
inhibitor (SB225002) mimics the effects of ciglitazone on growth inhibition (Fig. S4). 
 
Involvement of MITF in the regulation of CXCL1 expression by ciglitazone 
To further investigate the mechanism responsible for ciglitazone-induced CXCL1 
downregulation, we focused our attention on MITF that was recently reported to be regulated 
by some PPARγ agonists 22,23. Ciglitazone induced a dose-dependent reduction of MITF 
expression in both A375 and SK-Mel-28 melanoma cells (Fig. 7A). We demonstrated that 
MITF inhibition by ciglitazone was not due to its cleavage during apoptosis since the MITF 
decrease was observed after 2h of treatment, while PARP cleavage appeared clearly later 
(12h). To confirm this result we showed that the pan-caspase inhibitor Z-VAD-FMK 
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prevented melanoma cell death induced by ciglitazone treatment (Fig. S5) by preventing 
apoptosis induction monitored by PARP processing (Fig. 7A, Right panel). However, MITF 
inhibition evoked by ciglitazone was still observed in the presence of Z-VAD-FMK. Finally, 
using RT-QPCR, we also found a dose-dependent decrease of MITF expression confirming 
that ciglitazone inhibited MITF expression at the transcriptional level (Fig. 7B). 
We next checked whether MITF might control CXCL1 expression. MITF silencing by 
specific si-RNA induced a strong reduction of the MITF transcript and a concomitant 
reduction of CXCL1 gene expression (Fig. 7C). Melanoma cells transfected with a vector 
encoding for wild-type MITF revealed an increased in CXCL1 labeling by 
immunofluorescence (Fig. 7D). Consistently, forskolin or forskolin/IBMX that increased 
endogenous MITF level showed a significant increase in CXCL1 (Fig. 7E).  
To determine whether MITF controlled the CXCL1 promoter activity, we performed 
luciferase assays on melanoma cells using either tyrosinase or CXCL1 promoter upstream the 
luciferase coding sequence. Transfection with a dominant negative form of MITF (DN MITF) 
led to a decrease in both tyrosinase and CXCL1 promoter activity. The effect on CXCL1 
promoter was weak but significant. Conversely, transfection of A375 melanoma cells with the 
wild-type form of MITF (MITF) led to an upregulation of tyrosinase and CXCL1 promoter 
activity (Fig. 7F). 
Then, to verify the binding of MITF to the CXCL1 promoter in intact cells, we performed 
chromatin immunoprecipitation (ChIP) assays. Direct PCR amplification with specific 
primers spanning the CXCL1 promoter between -410 and +77, on total DNA extract or after 
immunoprecipitation with antibody to polymerase II as a positive control amplified a 500bp 
fragment (Fig. 7G). Alternatively, after immunoprecipitated with non-immune mouse IgG no 
amplification could be observed. After immunoprecipitation with anti-MITF, we amplified a 
band at 500bp corresponding to the CXCL1 promoter. The intensity of this band was clearly 
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decreased in extracts from cells exposed to ciglitazone but not in extracts from cells exposed 
to forskolin (Fsk). Conversely, using specific GAPDH promoter primers, we amplified 
160bp-fragment corresponding to the GAPDH promoter in both the total extract and the anti-
Pol II precipitates, but not in the anti-MITF precipitates. These results demonstrate that MITF 
binds to the CXCL1 promoter in intact cells and that this interaction is abolished by 
ciglitazone treatment. 
 
Effect of ciglitazone on circulating CXCL1 and melanoma tumor xenografts 
development in mice. 
Then, to determine the effect of ciglitazone on circulating CXCL1 and on tumor development 
in vivo, human A375 melanoma cells were injected subcutaneously in athymic nude mice. 
Nineteen days post injection, mice were treated with vehicle or ciglitazone (50mg/kg/day) 
during 11 days.   
Tumors from untreated mice dramatically grew throughout the time course of the study (Fig. 
8A). In contrast, treatment of mice with ciglitazone markedly attenuated the capacity of cells 
to develop visible tumors. Indeed, 3 out of 6 ciglitazone treated-mice did not have a 
measurable tumor at the end of the treatment. Moreover, visible tumors of other mice were 
significantly smaller compared to untreated control mice confirming that ciglitazone has anti-
melanoma activity in vivo. 
After mice sacrifice, RT-QPCR were performed on RNA extracted from tumors. 
Interestingly, MITF and CXCL1 gene expression were significantly lower in tumors of mice 
treated with ciglitazone (Fig. 8B). In parallel, we measured the quantity of serum CXCL1 
(Fig. 8C). A huge amount of circulating CXCL1 was detected in mice with human melanoma 
tumors compared to non-tumor bearing mice (no detectable human CXCL1). Further, no 
significant CXCL1 level was detected in mice treated with ciglitazone in comparison to 
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vehicle-treated mice. When we expressed the quantity of serum CXCL1 as a function of 
tumor volume, we observed a 3.5-fold significant reduction in the level of circulating CXCL1 
in ciglitazone-treated mice. Therefore, the decrease in CXCL1 serum level observed in 
ciglitazone-treated mice was not due to a decrease in tumor volume, but was likely a 
consequence of CXCL1 inhibition induced by ciglitazone. Finally, to unequivocally 
demonstrate the importance of CXCL1 downregulation in the in vivo effects of ciglitazone, 
we evaluated the effects of rCXCL1 peritumoral injections (200 ng/tumor/day for 14 days) on 
the development of tumors in mice treated or not with ciglitazone. As expected, treatment of 
mice with ciglitazone markedly impaired tumors development (Fig. 8D). However, rCXCL1 
treatment dramatically favored tumor development and abrogated anti-tumoral effects of 
ciglitazone. Injection of human recombinant CXCL1 therefore compensates for the decrease 
in endogenous CXCL1 level mediated by ciglitazone treatment and promotes tumor growth. 
This experiment clearly demonstrates the importance of CXCL1 expression in melanoma 
tumor development and highlight the pivotal role of CXCL1 downregulation in ciglitazone 
effects.
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Discussion 
Because metastatic melanoma are resistant to all currently used treatments, the 
discovery of new therapeutic drugs is a very important challenge. We and others have 
previously shown that ciglitazone, a molecule of the TZD family, is able to induce apoptosis 
independently of PPARγ activation and to inhibit proliferation of melanoma cells 12,24-26. In 
the present report, we have investigated the molecular mechanism by which ciglitazone exerts 
its anti-melanoma activity.  
Our results showed that conditioned media from ciglitazone-treated melanoma cells 
inhibit normal human melanocyte growth indicating that the effects of ciglitazone on 
melanoma cells are mediated by secreted factors. RT-QPCR screening demonstrating an 
inhibition of CXCL1 chemokine upon ciglitazone treatment prompted us to focus our 
attention on this cytokine. CXCL1, also named Melanoma Growth Stimulating Activity 
(MGSA) or Growth Regulated Oncogene alpha (GROα) belongs to the CXC family. CXCL1 
is essential for the establishment and the maintenance of the tumoral potential of melanoma 
27,28. The CXCL1 gene product is located within the CXCL1-3 gene cluster on chromosome 
4q12-q13 29. CXCL1, CXCL2 and CXCL3 bind with high affinity to a common receptor, 
CXCR2, with CXCL1 having the highest affinity for this receptor 30. Overexpression of 
CXCL1 in INK4a/ARF-/- mice favors melanoma development 31 and promotes malignant 
growth of murine squamous cell carcinoma by a CXCR2 dependent pathway 32. Blocking 
antibodies to either CXCL1 or CXCR2 inhibit melanoma cell growth demonstrating the key 
role of the CXCL1/CXCR2 signaling pathway in melanoma development 33,34. In addition to 
its autocrine role, CXCL1 has been shown to play an important paracrine role by regulating 
angiogenesis during tumor development including melanoma 35,36. 
First, we demonstrate that ciglitazone negatively regulates mRNA and protein CXCL1 levels. 
This inhibition is accompanied by a reduction of CXCL1 in the medium. The inhibition of 
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CXCL1 in response to ciglitazone precedes the decrease in cell viability, indicating that the 
decrease in CXCL1 expression induced by ciglitazone is not a consequence of cell death. A 
similar decrease in CXCL1 is also observed in response to troglitazone while rosiglitazone 
and pioglitazone have no significant effect on CXCL1 secretion. This result is in agreement 
with our previous report demonstrating that both rosiglitazone and pioglitazone have only 
marginal PPARγ dependent effect on viability of melanoma cells 12. Consistent with this 
finding, PPARγ silencing by siRNA does not abrogate the effects of ciglitazone on CXCL1 
expression, indicating that the regulation of CXCL1 is PPARγ independent. 
In normal human melanocytes, there is not basal CXCL1 production. Treatment of normal 
human melanocytes with TNFα stimulation increases CXCL1 secretion that is not affected by 
ciglitazone. Conversely, melanoma cells generally have a constitutive basal CXCL1 
expression mainly due to the NF-κB pathway constitutive activation 27. Independently of the 
mutational status, melanoma development stage or CXCL1 basal level, we found that 
ciglitazone inhibits CXCL1 production in all tested melanoma cell lines. Moreover, there is a 
positive correlation between the level of basal CXCL1 and the decrease in cell viability 
mediated by ciglitazone, suggesting that melanoma cells producing CXCL1 are addict to these 
cytokine. 
In the same way, in other cancer cell lines such as prostate carcinoma or neuroblastoma, 
ciglitazone also decreases CXCL1 level and cell viability. These results support the idea that 
inhibition of CXCL1 cytokine could play a general role in the anti-tumoral effects of 
ciglitazone.   
It has been proposed that some PPARγ agonists lead to inhibition of NF-κB activation 37-39, 
but in our system, the inhibition of CXCL1 by ciglitazone is not mediated by the down-
regulation of NF-κB activity (data not shown). Interestingly, a recent paper showed that 
ciglitazone led to a decrease in MITF expression 22 and in silico analysis of the CXCL1 
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promoter showed four potential E boxes that match with the consensus binding-site for MITF 
transcription factor (data not shown), thereby suggesting the possible involvement of MITF in 
the control of CXCL1 expression. These two observations promoted us to investigate the role 
of MITF in the regulation of CXCL1 by ciglitazone. First, ChIP experiments and luciferase 
assays demonstrate that MITF binds to and regulates the CXCL1 promoter. MITF silencing 
decreases CXCL1 messengers and inhibits CXCL1 protein secretion. Additional studies 
suggest that MITF interacts with the CXCL1 promoter through a responsive element 
(CAGGTG) at -375. 
Further, we have previously found that MITF is cleaved in response to the apoptosis inductor, 
TRAIL 40. MITF diminution that we observed in response to ciglitazone is not due to a protein 
cleavage by caspases since MITF decrease is seen before apoptosis induction and is also seen 
on mRNA level and in presence of pan-caspase inhibitor Z-VAD-FMK. These interesting 
results highlight a new specific pathway mediated by ciglitazone in melanoma cells. We have 
demonstrated that the negative regulation of MITF by ciglitazone is a PPARγ independent 
event. However, the precise mechanism responsible for this negative regulation of MITF is 
not known. One possible mechanism might involve downregulation of the Wnt/β-catenin 
pathway because this pathway is inhibited by some PPARγ agonists and might mediate the 
inhibition of MITF expression 22,23. Thus, considering all our results we demonstrate for the 
first time that the control of MITF expression by ciglitazone is involved in the inhibition of 
CXCL1 expression and secretion. This new signaling pathway involves MITF in the 
regulation of CXCL1 and strengthens the importance of this transcription factor in melanoma 
tumorigenicity. 
We have previously demonstrated that ciglitazone has cytostatic and cytotoxic effects 12. We 
found that both cell cycle arrest and apoptosis evoked by ciglitazone are reversed by addition 
of rCXCL1 or TNFα. These data suggest that ciglitazone effects on cell viability are mediated 
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mainly by a decrease in CXCL1 expression and secretion. In addition, rCXCL1 does not 
protect cells from apoptosis induced by TRAIL and staurosporine, suggesting a potential 
specificity of rCXCL1 on ciglitazone effects. The depletion of CXCL1 with siRNA is 
sufficient to mimic the biological effects of ciglitazone on A375 cells. Consequently, these 
results reinforce the hypothesis that inhibition of CXCL1 synthesis by ciglitazone is implied 
in the biological effects of this TZD. A second approach by CXCL1 neutralizing antibodies 
confirmed these results. Therefore, the reduction of secreted form of CXCL1 is involved in 
ciglitazone biological effects.  
At the molecular level, the stimulation of CXCR2 by CXCL1 induces activation of several 
transduction pathways, and particularly Raf/MEK/ERK and PI3K/Akt pathways 14. However, 
in most melanoma cells, Raf/MEK/ERK pathway is constitutively active due to oncogenic 
mutation on B-Raf 41. Consequently, this cytokine rather exerts its action on 
proliferation/survival through the activation of the PI3K/Akt pathway. 
Finally, we have evaluated the correlation between potential anti-melanoma activity of 
ciglitazone and CXCL1 secretion in a mouse model of melanoma xenografts. We have 
previously demonstrated that ciglitazone prevents tumor growth development 12. Importantly, 
our present results show that the short-term administration of ciglitazone not only prevents 
tumor formation but also reduces the volume of already established melanoma tumors. In 
addition, ciglitazone decreases MITF and CXCL1 mRNA level in tumor xenograft, reinforcing 
the hypothesis that in vivo, MITF is also involved in the control of CXCL1 mediated by 
ciglitazone. In parallel, we observe a drastic reduction of serum CXCL1 level in mice. This 
decrease is not due to the reduction of tumor growth because when we expressed the quantity 
of CXCL1 as a function of tumor size, we still found a reduction of circulating CXCL1 in 
ciglitazone-treated mice. Moreover, injection of CXCL1 in ciglitazone treated mice 
compensates for the loss of endogenous CXCL1, impairing the effects of ciglitazone and 
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preventing the decrease in tumor volume. From these observations, we can propose that the 
decrease in CXCL1 secretion mediated by ciglitazone might be responsible for the 
antineoplastic effects of this TZD in vivo. 
In summary, we demonstrate for the first time that ciglitazone inhibits tumor growth through a 
negative regulation of the MITF/CXCL1/CXCR2 axis signaling pathway. This demonstration 
brings new and additional clues to the mechanism of ciglitazone-induced melanoma cell 
death. Finally, taking into account the drastic effect of ciglitazone on melanoma cell growth, 
survival and anti-melanoma xenograft development, it might be worth evaluating ciglitazone 
treatment in patients with metastatic melanoma. Our reports also highlight the pivotal role of 
tumor cell-produced CXCL1 in melanoma cell proliferation and support the idea that CXCL1 
might be used as a new progression marker in the follow-up of the metastatic melanomas. 
Because the overexpression of CXCL1 and the CXCL1-regulation by ciglitazone are not 
specific to the melanomas, our study, besides its interest in melanoma pathology, contributes 
to better understand the general anti-cancer effects of ciglitazone. 
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Material and methods 
 
Materials 
Ciglitazone, Troglitazone and Z-VAD-FMK were purchased from Biomol (Tebu, Le Perray 
en Yvelines, France). Pioglitazone and Rosiglitazone were from Cayman Chemical Company 
(Ann Arbor, MI, USA). Dimethyl sulfoxide (DMSO), staurosporine, forskolin, 3-Isobutyl-1-
methylxanthine (IBMX), hydrocortisone, insulin, phorbol-12 myristate 13-acetate, MCDB 
153 medium, sodium fluoride, dimethylacetamide, Hoechst 33258, tween 80, sodium 
orthovanadate, 4-(2-aminoethyl)-benzene-sulfonyl fluoride (AEBSF), aprotinin and leupeptin 
were purchased from Sigma-Aldrich (Saint Quentin Fallavier, France). Labrafil M 1944 Cs 
was purchased from Gattefossé (Saint-Priest, France). The caspase substrates and the caspase 
inhibitors were from MERCK Eurolab (Fontenay-sous-Bois, France). Trypan blue, 
Dulbecco's Modified Eagle's Medium (DMEM), penicillin/streptomycin and trypsin were 
from Invitrogen (Pontoise, France); Fetal Calf Serum (FCS) from Hyclone (Brevieres, 
France). TRAIL was obtained from R&D Systems (Lille, France). Recombinant human TNFα 
and recombinant human CXCL1 were purchased from Peprotech (Neuilly-sur-Seine, France). 
 
Cell cultures     
Normal human melanocytes were prepared and maintained as described 42. Human A375 
(CRL-1619TM), SK-Mel-28 (HTB-72TM) and MeWo (HTB-65TM) melanoma cells, prostate 
cancer PC-3 (CRL-1435TM) and neuroblastoma SH-SY5Y (CRL-2266TM) cell lines were 
purchased from American Tissue Culture Collection (Molsheim, France) and grown in 
DMEM medium supplemented with 10% FCS and penicillin/streptomycin (100U/ml/50 
µg/ml). Human WM793 vertical growth phase melanoma cell line and 1205 Lu metastatic 
melanoma cell line were generously provided by Dr M. Herlyn (Wistar Institute, Philadelphia, 
PA) and maintained as described 43. For each experiment, cells were starved in appropriate 
medium without FCS during 14 hours before drug stimulation. 
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Antibodies.  
HSP60 was from Santa Cruz Biotechnology (TEBU; Le Perray en Yvelines, France). The 
polyclonal pro-caspase 9, monoclonal pro-caspase 8, monoclonal pro-caspase 3 and 
polyclonal PARP antibodies were from Cell Signaling Technology (Ozyme, Saint-Quentin-
en-Yveline, France). Monoclonal anti-SPARC was purchased from Haematologic 
Technologies Inc. (Essex Junction, VT, USA). Monoclonal MITF was purchased from Spring 
Bioscience (Fremont, CA, USA). Monoclonal CXCL1 and CXCR2 were purchased from 
R&D Systems (Lille, France). 
 
Real-time quantitative PCR (Q-PCR) 
For gene array analysis, total RNA was isolated using TRIZOL® (Invitrogen). After treatment 
with Dnase I, 2 μg of RNA were reverse transcribed using the High Capacity cDNA Archive 
random priming Kit (Applied Biosystems). The expression level of 19 genes related to 
melanoma secretome was evaluated using an ABI Biosystems 7900HT Sequence Detector 
System and the SYBR Green dye detection protocol as outlined by the manufacturer (Applied 
Biosystems). Gene-specific primers were designed using the Primer Express software 
(Applied Biosystems). Relative expression level of target genes was normalized for RNA 
concentrations of four different housekeeping genes (GAPDH, β-actin, HPRT and ubiquitin). 
For each sample, CT values for the housekeeping genes were determined for normalization 
purposes, and delta CT (ΔCT) between the mean of housekeeping genes values and target 
genes values was calculated. Relative expression level of target genes mRNA between DMSO 
control cells (DMSO) and ciglitazone treated cells (cigli.) was calculated using the formula 
ΔCTCigli.– ΔCTDMSO and expressed as fold over control (2ΔΔCT). Values represent the 
mean of duplicates and are representative of two independent experiments. Other Q-PCR 
were performed exactly as described 44. 
19 
 
 
Cell viability test 
Cell viability was assessed using the Cell Proliferation Kit II (XTT; Roche Diagnostics, 
Meylan, France) according to the manufacturer’s protocol. Cell viability is expressed as the 
percentage of the value in DMSO-treated cells. 
 
ELISA 
CXCL1 ELISA were performed using Quantikine® Human CXCL1/GROα from R&D 
Systems (Lille, France) according to the manufacturer’s protocol. 
 
Immunoflurescence microscopy 
Monolayers prepared for fluorescent staining were grown on glass coverslips. 
Immunofluorescence experiments were carried out as described 12. 
 
Western blot assays 
Western blot analyses were performed as described 12. 
 
Caspase activity  
Caspase activities were carried out exactly as described 12. 
 
Flow cytometry analysis 
All flow cytometry analyses were performed using the FL2 channel of a FACScan (Becton 
Dickinson; Cowley, UK) and data were analyzed with CellQuest software as previously 
described 12. Annexin-V staining was performed using Annexin-V-FLUOS Staining Kit 
(Roche Diagnostics, Meylan, France) according to the manufacturer’s protocol.  
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Small interfering RNA 
Small interfering RNAs (siRNAs) experiments were carried out exactly as described 12. 
siRNA targeting CXCL1 was from Santa Cruz Biotechnology (sc-43816). siRNA targeting 
MITF was described previously 40. As nonspecific control, a scramble sequence for CXCL1 
or MITF siRNA was used.  
 
Construction of the CXCL1 reporter plasmid 
A 1.5-kb fragment 5’ of the transcriptional site of the CXCL1 gene was amplified by PCR 
reaction and isolated by Topo® Cloning Kit (Invitrogen) from genomic DNA. The 1.5-kb 
XhoI/SacI fragment was then subcloned using Rapid DNA Ligation Kit (Roche) into the 
unique XhoI/SacI restriction site of the Promega pGL3 basic vector (pGL3b) upstream of the 
luciferase coding sequence (pCXCL1; -1477/+77).  
 
Transfections and luciferase assays 
Transfections and luciferase assays were performed as described 12. The reporter plasmid 
containing the 2.2-kb fragment of the mouse tyrosinase promoter (pTyro; −2,236/+59) was 
described elsewhere 45. Plasmids coding for microphthalmia coding sequence (WT Mitf) or its 
dominant negative form containing an inframe deletion of the NH2-terminal domain (DN 
Mitf) in pCDNA3 expression vector are described elsewhere 18. 
 
Chromatin Immunoprecipitation Assay 
 
SK-Mel-28 cells were cultured in 100-cm2 culture dishes, stimulated or not with ciglitazone 
or forskolin for 24 h, and then treated with 1% formaldehyde for 10 min at room temperature. 
Next, the cells were harvested, centrifuged (700 X g, 5 min at 4 °C), and resuspended in SDS 
lysis buffer (EZ-ChIPTM Chromatin Immunoprecipitation Kit; Upstate). After sonication the 
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sheared chromatin was immunoprecipitated using indicated antibody. Then, protein/DNA 
cross-linking complexes were reversed by heat treatment (65°C overnight) and proteinase K 
digestion. The genomic captured fragments were purified using spin columns. Identification 
of the captured DNA fragments was performed by PCR analysis using the CXCL1 or 
GAPDH promoter primers. Thirty-two cycles of PCR were performed, and the amplified 
products were analyzed on a 2.5% agarose gel. 
 
In vivo murine cancer model 
Animal experiments were carried out in accordance with the Declaration of Helsinki and were 
approved by a local ethical committee. Female immune-deficient BALB/c nu/nu (nude) mice 
were obtained at 6 weeks of age from Harlan Laboratory.  
Mice were inoculated subcutaneously with A375 melanoma cells (2.5x106 cells/mouse). After 
19 days, animals received intraperitoneal injection of ciglitazone (50 mg/kg/day) dissolved in 
a mixture of Labrafil M 1944 Cs (an amphiphilic oil, Oleic Macrogol-6 Glyceride), 
dimethylacetamide, and Tween 80 (90:9:1%, vol/vol/vol) as previously described 46.  
The growth tumor curves were determined by measuring the tumor volume using the equation 
V= (LxW2)/2. After 11 days of treatment, mice were bled and sera were analyzed using 
ELISA of CXCL1. At the end of the experiment, mice were killed by CO2 inhalation and 
tumors were taken for RNA extraction. 
 
Statistical analysis 
Data presented are mean +/-SD of three independent experiments performed in triplicate. 
Statistical significance was assessed using the Student’s t-test except for in vivo experiments 
in which statistical significance was assessed using two-tailed Wilcoxon rank sum test. A 
value of p < 0.05 was accepted as statistically significant. 
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Figure Legends 
 
Figure 1: Ciglitazone modifies melanoma cell secretome. 
a) Starved normal human melanocytes (NHM) were treated or not with 10µM ciglitazone 
(Cigli.) for 96 hrs. Cells were then harvested and counted using trypan blue. Results are 
expressed in percent of control (100%). 
b) Starved A375 melanoma cells were treated or not with 10µM ciglitazone for 24 hours. 
Conditioned media were collected and centrifuged for 5 minutes at 2000 rpm. Supernatants 
were immediately added to the culture medium of NHM (1:1). After 96 hours, NHM were 
harvested and counted using trypan blue. Results are expressed in percent of control (100%). 
Data are mean +/- SD of three independent experiments performed in triplicate. Significantly 
different from the corresponding control ** p< 0.01.  
Figure 2: Ciglitazone decreases CXCL1 level in A375 melanoma cells. 
Starved A375 melanoma cells were treated for 24 hours with various concentrations of 
ciglitazone or TNFα (10ng/ml). 
a) Total RNA was extracted and analyzed by real-time quantitative PCR using CXCL1 
primers. mRNA expression was normalized using SB34 RNA level. Results are expressed as a 
mean +/- SD from 3 independent experiments. Significantly different from the corresponding 
control * p< 0.05; ** p< 0.01; *** p< 0.001. 
b) A375 cells were fixed and stained for CXCL1 or CXCR2 (green) and with DAPI (blue). 
DAPI staining was used to identify cell nucleus. Right panels show merge of DAPI and 
CXCL1 or CXCR2 staining. Slides were examined with a Zeiss Axiophot fluorescence 
microscope and pictures were taken at X200 magnification. Representative field of three 
different experiments are shown. 
c) ELISA of CXCL1 was performed on supernatants from starved A375 melanoma cells 
treated as indicated. Data are mean +/- SD of three independent experiments performed in 
triplicate. SPARC western blotting on those supernatants was used as loading control. 
Significantly different from the corresponding control * p< 0.05; *** p< 0.001.  
Figure 3: CXCL1 expression in response to various TZD and in different cell lines 
a) Time course of XTT activity (upper panel) and ELISA assay for CXCL1 (lower panel) 
were performed on starved A375 melanoma cells treated for different times with 1 or 10 µM 
ciglitazone or with staurosporine. Results are expressed in percent of control (100%) for each 
time. Data are mean +/- SD of three independent experiments performed in triplicate.  
b) ELISA of CXCL1 was performed on supernatants from starved A375 melanoma cells 
treated for 24 hours with different TZD: ciglitazone (Cigli.), pioglitazone (Pio.), rosiglitazone 
(Rosi.), troglitazone (Trogli.). Results are expressed in percent of control (100%) for each 
time. Data are mean +/- SD of three independent experiments performed in triplicate.  
c) ELISA of CXCL1 was performed on supernatants from starved normal human melanocytes 
(NHM) treated or not for 24 hours with various concentrations of ciglitazone added or not 
with TNFα 10 ng/ml. Data are mean +/- SD of three independent experiments performed in 
triplicate.  
27 
 
d) ELISA of CXCL1 was performed on supernatants from different cell lines treated or not 
for 24 hours with 10μM of ciglitazone added or not with TNFα 10 ng/ml. Data are mean +/- 
SD of three independent experiments performed in triplicate. Significantly different from the 
corresponding control * p< 0.05; ** p< 0.01; *** p< 0.001; # p< 0.05. 
e) Starved cells from various cell lines were treated or not with 10µM ciglitazone for 60 hrs. 
Cells were then harvested and counted using trypan blue. Results are expressed in percent of 
control (100%). Data are mean +/- SD of three independent experiments performed in 
triplicate.  
Figure 4: Recombinant CXCL1 is sufficient to abrogate decrease of cell viability induced 
by ciglitazone. 
XTT activity was performed on starved A375 melanoma cells treated with ciglitazone 10µM 
added or not with various concentrations of recombinant CXCL1 (a), 10 ng/ml TNFα (b) or 
treated with various concentrations of TRAIL or staurosporine added with 50 ng/ml of 
recombinant CXCL1 (c). Results are expressed in percent of control (100%) for each time. 
Data are mean +/- SD of three independent experiments performed in triplicate. Significantly 
different from the corresponding control * p< 0.05; *** p< 0.001. 
Figure 5: Recombinant CXCL1 is sufficient to abrogate apoptosis induced by 
ciglitazone. 
Starved A375 melanoma cells were treated for 24 hours with various concentrations of 
ciglitazone added or not with 50 ng/ml of recombinant CXCL1 (rCXCL1). 
 
a) Western blot was performed on cell lysates (30 μg total protein per lane). Proteins were 
separated by 10% SDS-PAGE and analyzed by western blot using the indicated antibody. 
HSP60 was used as loading control. One representative experiment of three is shown. 
 
b) Caspase 3, 8 and 9 activities were performed on cell lysates (30µg per condition). Lysate 
from cells treated for 5 hours with 1 µM staurosporine was used as positive control of 
caspases activation. Results are expressed in relative fluorescence units per minute and per 
mg of protein (UAF/min/mg of prot.). Data are mean +/- SD of three independent experiments 
performed in triplicate. Significantly different from the corresponding control; ** p< 0.01; 
*** p< 0.001; # p< 0.05. 
c) Cells were detached and stained with Annexin-V-Fluorescein before being analyzed by 
flow cytometry. Data are representative of three independent experiments performed in 
triplicate. 
Figure 6: Inhibition of CXCL1 decreases cell viability. 
a) Starved A375 cells were transfected for 48 hours with various concentrations of siRNA 
targeting CXCL1 (si-CXCL1) or a scramble sequence (si-CT). ELISA for CXCL1 was 
performed on supernatants from transfected cells. Results are expressed in percent of control 
(100%). Data are mean +/- SD of three independent experiments performed in triplicate. 
SPARC western blotting on those supernatants was used as loading control. Significantly 
different from the corresponding control *** p< 0.001. 
b) XTT activity was performed on starved A375 transfected for 48 hours with various 
concentrations of siRNA targeting CXCL1 and added or not with rCXCL1 (50 ng/ml). 
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Results are expressed in percent of cells transfected with the control siRNA (100%) for each 
concentration. Data are mean +/- SD of three independent experiments performed in triplicate. 
Significantly different from the corresponding control * p< 0.05; *** p< 0.001. 
c) XTT activity was performed on starved A375 treated for 24 hours with various 
concentrations of blocking antibody targeting CXCL1. Results are expressed in percent of 
control (100%). Data are mean +/- SD of three independent experiments performed in 
triplicate. Significantly different from the corresponding control * p< 0.05; *** p< 0.001. 
d) Caspase 3, 8 and 9 activities were performed on cell lysates (30µg per condition) from 
starved A375 transfected for 48 hours with various concentrations of control (CT) or CXCL1 
siRNA. Results are expressed in relative fluorescence units per minute and per mg of protein 
(UAF/min/mg of prot.). Data are mean +/- SD of three independent experiments performed in 
triplicate. Significantly different from the corresponding control *** p< 0.001.  
e) Starved A375 cells were transfected for 48 hours with 50nM of siRNA targeting CXCL1 
(si-CXCL1) or a scramble sequence (si-CT). Cells were detached and stained with Annexin-
V-Fluorescein before being analyzed by flow cytometry. Data are representative of three 
independent experiments performed in triplicate. 
 
Figure 7: Decrease of CXCL1 mediated by ciglitazone involves MITF transcription 
factor. 
a) On left panel, starved A375 or SK-Mel-28 melanoma cells were treated or not with 10µM 
ciglitazone (Cigli.) at different times. On right panel, starved SK-Mel-28 were treated for 24 
hours with DMSO or ciglitazone added or not with 100µM Z-VAD-FMK. 
Proteins were separated by 12% SDS-PAGE and analyzed by western blot using the indicated 
antibody. HSP60 was used as loading control. One representative experiment of three is 
shown.  
 
b) Total RNA from starved A375 cells treated for 24 hours with various concentrations of 
ciglitazone was extracted and analyzed by real-time quantitative PCR using MITF primers. 
mRNA expression was normalized using SB34 RNA levels. Results are expressed as a mean 
+/- SD from 3 independent experiments. Significantly different from the corresponding 
control * p< 0.05; *** p< 0.001. 
 
c) Total RNA from starved A375 cells transfected for 48 hours with siRNA targeting MITF 
(si-MITF) or its scramble sequence (si-CT) was extracted and analyzed by real-time 
quantitative PCR using MITF and CXCL1 primers. mRNA expression was normalized using 
SB34 RNA level. Results are expressed as a mean +/- SD from 3 independent experiments. 
Significantly different from the corresponding control *** p< 0.001. 
 
d) A375 cells transfected with the wild type form of MITF were fixed and stained for MITF 
(green), CXCL1 (red) and with DAPI (blue). DAPI staining was used to identify cell nucleus. 
Slides were examined with a Zeiss Axiophot fluorescence microscope and pictures were taken 
at X200 magnification. Representative field of three different experiments are shown. 
e) Starved A375 melanoma cells were treated or not with 20µM forskolin (Fsk) added or not 
with 100µM IBMX for 7 hours. ELISA of CXCL1 was performed on supernatants from 
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starved A375 melanoma cells treated as described. Results are expressed in percent of control 
(100%). Corresponding proteins were separated by 12% SDS-PAGE and analyzed by western 
blot using the indicated antibody. HSP60 was used as loading control. One representative 
experiment of three is shown. Significantly different from the corresponding control *** p< 
0.001. 
f) A375 cells were transfected with vector encoding the basal luciferase construct (Mock), 
wild type MITF (WT MITF) or its dominant negative form (DN MITF) and with pTyro or 
pCXCL1 luciferase reporters. Measurement of luciferase activity was carried out 36 hours 
after transfection. Variability of transfection was normalized with βGal activity and results 
were expressed in percent of control (100%). Data are mean +/- SD of three independent 
experiments performed in triplicate. Significantly different from the corresponding control ** 
p<0.01; *** p< 0.001. 
g) Chromatin immunoprecipitation assays were performed on extracts of cells treated for 24 
hours with DMSO, 10µM ciglitazone (Cigli.), or with 20µM forskolin (Fsk) for 7 hours. 
Immunoprecipitations were performed using specific anti-MITF or anti-polymerase II (Pol II) 
antibody, and rabbit IgG (IgG) as control. Primers spanning the CXCL1 promoter region were 
used for the PCR amplification. A control of PCR amplification was performed on non-
immunoprecipitated extracts (Input). Another control was performed using a primer pair to 
the human GAPDH promoter. 
Figure 8: In vivo antineoplastic effects of ciglitazone correlate with decrease of MITF 
and CXCL1 expression. 
a) Mice were inoculated subcutaneously with A375 melanoma cells (2.5 x 106), and after 19 
days animals (n=6 in each group) were treated with ciglitazone (50 mg/kg/day) or labrafil for 
11 days. Growth tumor curves were determined by measuring the tumor volume using the 
equation V= (LxW2)/2. Significantly different from the corresponding control * p< 0.05; ** 
p< 0.01. 
b) Total RNA was extracted from mice tumors and analyzed by real-time quantitative PCR 
using CXCL1 primers. mRNA expression was normalized using SB34 RNA level. 
Significantly different from the corresponding control *** p< 0.001. 
c) ELISA for CXCL1 was performed on mice sera from bleeding after 11 days of ciglitazone 
or labrafil treatment. Sera from non tumor-bearing animals were used as negative control. 
Data are mean +/- SD of 6 samples collected in each group. Significantly different from the 
corresponding control * p< 0.05. Ratio serum CXCL1/tumor volume (right panel). 
d) Mice were inoculated subcutaneously with A375 melanoma cells (2.5 x 106), and after 12 
days animals (n=6 in each group) received intraperitoneal injection of ciglitazone (50 
mg/kg/day) or labrafil and subcutaneous peritumoral injections of human recombinant 
CXCL1 (200 ng/tumor/day) or water for 14 days. Growth tumor curves were determined by 
measuring the tumor volume using the equation V= (LxW2)/2. Significantly different from 
Labrafil/H2O * p< 0.05; ** p< 0.01. Significant difference between Ciglitazone/H2O and 
Ciglitazone/CXCL1 # p< 0.05; ## p< 0.01. 
Table 1: Genes differentially expressed in melanoma cells stimulated or not with 
ciglitazone.  
The expression level of 19 genes from proteins secreted by melanomas was evaluated by real- 
time quantitative PCR analysis. Total RNA was extracted from A375 cells stimulated or not 
30 
 
with ciglitazone for 24 hours and then subjected to real-time quantitative PCR analysis as 
described in methods. Data are expressed in arbitrary units as fold change between DMSO-
treated control cells and ciglitatone-treated cells and are a mean of two independent 
amplifications performed in duplicate. 
 
 
 
 
 






















